$SHC

Sotera Health (SHC) reported Q2 2026 revenue of $321.38 million, up from $294.34 million, and net income of $53.64 million versus $7.96 million a year earlier. The company cited strength across Sterigenics, Nordion, and Nelson Labs and raised its full-year outlook. The article also notes a May 2026 repricing of first lien term loans and discusses regulatory and litigation risks tied to ethylene oxide.

Sotera Health Co (SHC) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. shc-20260811 0001822479 FALSE 0001822479 2026-08-11 2026-08-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _______________________ FORM 8-K _______________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Da

China is accelerating brain-computer interface (BCI) development via state-backed initiatives. PICC Property and Casualty, a state-owned insurer, said it signed China’s first commercial insurance policy covering invasive BCI implant surgery, with a hospital affiliated with Zhejiang University in Hangzhou. BCI-linked Hong Kong stocks rose 1.59% on Wednesday, including Shanghai Heartcare (+1.28%) and BrainAurora (+1.65%).

Rutz Michael P (President of Sterigenics) sold 150,000 shares of Sotera Health Co (SHC) at $18.84 ($2.83M total) on 2026-08-07.

McIntyre Partnerships’ Q2 2026 investor letter highlighted Sotera Health (NASDAQ:SHC). It cited Sterigenics returning to HSD organic growth, Georgia litigation where a judge dismissed 5 lawsuits, and a CEO transition. The article notes SHC closed at $18.86 on Aug. 7, 2026, and discusses an estimated sub-$50M current liability and ~$180M worst-case settlement versus ~$640M 2026 EBITDA.

Sotera Health’s management said Q2 results reflected execution across Sterigenics, Nordion and Nelson Labs, helped by improved pricing and capacity investments. It completed a CEO transition, with Alton Shader replacing Michael Petras. Sterigenics demand was stable, Nordion benefited from Cobalt-60 shipment timing, and Nelson Labs gained from new customer projects. Guidance cites volume growth, inflation and litigation risks.

Sotera Health (NASDAQ:SHC) reported Q2 CY2026 revenue of $321.4 million, up 9.2% year over year, exceeding Wall Street estimates by 3.8%. Non-GAAP adjusted EPS was $0.26, up from $0.20, beating consensus by 8.7%. The company guided full-year revenue to about $1.25 billion, near analysts’ expectations.

Sotera Health (Nasdaq: SHC) reported Q2 2026 net revenues up 9.2% (8.0% constant currency) to $?, with net income $54 million ($0.19/share) versus $8 million ($0.03) a year earlier. Adjusted EPS was $0.26, and Adjusted EBITDA margin rose to 51.6%. The company raised FY 2026 outlook for net revenues to $1.236-$1.254B and Adjusted EBITDA to $634-$643M.

Sotera Health Co (SHC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 august62026-ex991.htm EX-99.1 Document Exhibit 99.1 Sotera Health Delivers Strong Second-Quarter and First-Half 2026 Results and Raises FY 2026 Outlook • Q2 2026 net revenues increased 9.2% or 8.0% on a constant currency basis (1) compared to Q2 2025 • Q2 2026 net incom

San Diego County’s unemployment rate fell to 3.9% in May, the lowest in over two years, state labor officials said, down from a revised 4.1% in April. The county added 4,300 jobs, led by leisure and hospitality (+3,600). Other gains included construction (+900) and government (+600). The labor force fell to 1.64 million. Job ads showed Northrop Grumman led with 109 postings; Qualcomm had 870.